In a significant milestone, Searle Company Limited (SEARL) has achieved the distinction of becoming the first pharmaceutical company from Pakistan to register its manufacturing facility in the United Arab Emirates (UAE) market. The UAE Ministry of Health and Prevention granted approval for the registration, marking a breakthrough for Pakistani pharmaceutical exports.
The news was celebrated by industry leaders and regulatory authorities alike. Chief Executive Officer of the Drug Regulatory Authority of Pakistan (DRAP), Asim Rauf, praised the achievement on “X” (previously Twitter), emphasising the significance of this milestone. He stated, “Yet another achievement. Pakistani pharma is now entering stringent markets. Searle’s recent certification is testimony to our commitment to boost pharma exports.”
The registration, valid until September 10, 2028, under Article 65 of Federal Law No 3 of 1984, signifies Searle’s compliance with UAE health and safety standards. The registered activities for Searle’s manufacturing facility include primary packaging, dosage form manufacturing, packaging and labelling, storage and handling, laboratory testing, batch release certification, and secondary packaging.
According to Searle, this achievement will facilitate exports to the UAE and Middle East region. The company has already appointed a distributor, and with the license in hand, product dossiers are being prepared.
Published in The Express Tribune, September 17th, 2023.
Like Business on Facebook, follow @TribuneBiz on Twitter to stay informed and join in the conversation.
1719053250-0/BeFunky-collage-(5)1719053250-0-270x192.webp "non solar consumers bear rs200b burden")
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ